Silicon Valley's fascination with longevity has given rise to a new player in the preventive health space: Biograph, a startup co-founded by renowned longevity scientist Dr. Peter Attia and prominent Silicon Valley figure John Hering. Emerging from stealth mode, Biograph is positioning itself as the world's "most advanced" preventive health and diagnostics clinic, with a location already operational in Silicon Valley and plans to expand to New York City this quarter and globally in the future.

Biograph's ambitious goal is to collect over 1,000 data points across 30+ evaluations to provide a holistic picture of an individual's health and optimize their lifespan. This comprehensive approach comes at a cost, with the startup's Core membership priced at $7,500 per year and its premium Black membership, which promises the "deepest insights," running $15,000 annually. Despite the hefty price tag, Biograph claims that over 15% of its members have already reported discovering "urgent or life-alerting health" insights through its services.

The startup's origins can be traced back to a personal experience of its CEO and co-founder John Hering, who was inspired to launch Biograph after his friend and Vy Capital partner Alexander Tamas received an early thyroid cancer diagnosis in his late 30s. Tamas' diagnosis, which was caught during a routine check-up, likely saved his life and prompted Hering to take proactive steps towards his own health. This experience sparked Hering's vision for Biograph, which aims to empower individuals with actionable health insights and preventive measures.

Biograph has assembled a formidable team, including executive medical director Michael Doney, a doctor with a background in longevity. The startup is also backed by a notable list of investors, including Vy Capital, Human Capital, Alpha Wave, and Wndr Co, as well as angel investors such as Balaji Srinivasan. Although Biograph declined to disclose the exact amount of funding it has raised, the startup's impressive roster of backers suggests a significant investment in its mission.

While Biograph's announcement does not explicitly mention AI, the company is actively seeking a founding AI engineer to develop an AI-powered assistant, according to its careers page. This move hints at the startup's plans to leverage artificial intelligence in its diagnostic and health optimization efforts, potentially enhancing the accuracy and personalization of its services.

Biograph's emergence is part of a larger trend in the startup ecosystem, with a growing number of companies focused on longevity and preventive health. Notable examples include Function Health, which is seeking a $2 billion valuation this year, and Retro Biosciences, which is in talks to raise $1 billion. As the longevity space continues to gain momentum, Biograph's innovative approach and high-profile backing position it as a key player in the industry's future.

As the startup expands its operations and develops its AI capabilities, it will be interesting to observe how Biograph's premium model resonates with consumers and whether its focus on preventive health and longevity can drive meaningful change in the healthcare landscape. With its ambitious vision and notable backers, Biograph is undoubtedly a startup to watch in the years to come.